Skip to main content
SpringerLink
Log in

Preoperative Therapy for Operable Breast Cancer

  • Chapter
  • First Online:
Breast Disease

  • 1621 Accesses

Abstract

Preoperative systemic chemotherapy (PSC), also known as “neoadjuvant chemotherapy,” is an important therapy option for most patients with breast cancer. PSC has evolved as an integral part of the multidisciplinary treatment approach for breast cancer and has a long history that dates back nearly four decades. Despite previous beliefs that it is more suitable for locally advanced or inflammatory disease, PSC is becoming increasingly popular in the breast oncology community for the treatment of earlier-stage disease. As safe and effective as adjuvant chemotherapy, this approach not only has the advantage of facilitating breast-conserving surgery (BCS) for patients in whom an optimal cosmetic outcome with upfront surgery is not possible but also has the potential to improve drug delivery to the tumor site by retaining intact vasculature before any local intervention is made. Furthermore, PSC provides an ideal setting in which the responsiveness of a given treatment can be observed and provides relevant information on the biology of the tumor by enabling biomarker analysis. Accumulating data on the strong association with survival and pathological complete response (pCR) may lead to a change in the regulatory requirements for drug approval and, consequently, reduce the need for costly and time-consuming large adjuvant trials.

 In conclusion, PSC is a valuable research tool for identifying predictive molecular biomarkers and a valid treatment option for patients with early-stage breast cancer. However, the decision to treat a patient with neoadjuvant chemotherapy requires careful clinical judgment and multidisciplinary evaluation by an experienced team.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.

    Article  PubMed  Google Scholar 

  2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224–37.

    PubMed  Google Scholar 

  3. Bear HD, Anderson S, Smith RE, Geyer Jr CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27.

    Article  CAS  PubMed  Google Scholar 

  4. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474–81.

    Article  CAS  PubMed  Google Scholar 

  5. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.

    Article  PubMed  Google Scholar 

  6. Untch M, Mobus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938–45.

    Article  PubMed  Google Scholar 

  7. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.

    CAS  PubMed  Google Scholar 

  8. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–85.

    CAS  PubMed  Google Scholar 

  9. Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91(12):2012–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b–T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53–9.

    Article  PubMed  Google Scholar 

  11. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, EORTC, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21(5):843–50.

    Article  CAS  PubMed  Google Scholar 

  12. Romieu G, Tubiana-Hulin M, Fumoleau P, Dieras V, Namer M, Mauriac L, et al. A multicenter randomized phase II study of 4 or 6 cycles of adriamycin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of breast cancer (BC). Ann Oncol. 2002;13 Suppl 5:33–9.

    Article  Google Scholar 

  13. Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004;22(24):4958–65.

    Article  PubMed  Google Scholar 

  14. Steger GG, Kubista E, Hausmaninger H, Gnant M, Tausch C, Lang A et al. 6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14 [abstract]. 2004;22 (Jul 15 Suppl 14S):A553.

    Google Scholar 

  15. Han S, Kim J, Lee J, Chang E, Gwak G, Cho H, et al. Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer. Eur J Surg Oncol. 2009;35(6):583–7.

    Article  PubMed  Google Scholar 

  16. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005;23(13):2988–95.

    Article  CAS  PubMed  Google Scholar 

  17. von Minckwitz G, Raab G, Caputo A, Earl H, Cameron DA, Hutcheon AW, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.

    Article  Google Scholar 

  18. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20(6):1456–66.

    Article  CAS  PubMed  Google Scholar 

  19. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, German Breast Group, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542–51.

    Article  Google Scholar 

  20. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, on behalf of; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann Oncol. 2011;22(9):1999–2006.

    Article  CAS  PubMed  Google Scholar 

  21. von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28(12):2015–23.

    Article  Google Scholar 

  22. Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, Melbinger-Zeinitzer E, et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res. 2009;69(24 Suppl):564s (abstract 1081).

    Google Scholar 

  23. Bear HD, Tang G, Rastogi P, Geyer Jr CE, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366(4):310–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li Q, Jiang Y, Wei W, Yang H, Liu J. Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(1):e53403. doi:10.1371/journal.pone.0053403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125(1):145–56.

    Article  Google Scholar 

  26. Earl HM, Vallier A, Hiller L, Fenwick N, Iddawela M, Hughes-Davies L, et al. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol. 2009;27:15s (abstract 522).

    Article  Google Scholar 

  27. Chua S, Smith IE, A’Hern RP, Coombes GA, Hickish TF, Robinson AC, et al. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol. 2005;16:1435–41.

    Article  CAS  PubMed  Google Scholar 

  28. Snider JN, Sanchev JC, Allen JW, Schwartzberg LS, Young RR, Javed AY et al. Pathologic complete response with weekly nanoparticle albumin bound paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide with concurrent bevacizumab for triple negative breast cancer. J Clin Oncol (meeting abstracts). 2013;31 (Suppl) (abstract 1068).

    Google Scholar 

  29. Mrozek E, Lustber MB, Knopp MV, Spigos DG, Yang X, Houton LA et al. Phase II trial of neoadjuvant chemotherapy with weekly nanoparticle albumin bound paclitaxel, carboplatin and bevacizumab in women with clinical stages II–III breast cancer: pathologic response prediction by changes in angiogenic volüme by dynamic contrast enhanced magnetic resonance imaging. J Clin Oncol (meeting abstracts). 2010;28(Suppl) (abstract 604).

    Google Scholar 

  30. Sinclair NF, Abu-Khalaf MM, Rizack T, Rosati K, Chung G, Legare RD et al. Neoadjuvant weekly nanoparticle albumin bound paclitaxel, carboplatin plus bevacizumab with or without dose-dense doxorubicin-cyclophosphamide plus B in ER+/Her-2 negative and triple negative breast cancer: a BrUOG study. J Clin Oncol (meeting abstracts). 2012;30(Suppl) (abstract 1045).

    Google Scholar 

  31. Untch M, Jackisch C, Schneeweiß A, Conrad B, Aktas B, Denkert C, et al. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. 37th San Antonio Breast Cancer Conference 9–13 Dec 2014, San Antonio; Meeting Abstract (S2–07).

    Google Scholar 

  32. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.

    Article  CAS  PubMed  Google Scholar 

  33. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.

    Article  CAS  PubMed  Google Scholar 

  34. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024–31.

    Article  CAS  PubMed  Google Scholar 

  35. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  36. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C et al. NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:(9816):633–40. Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D et al. Clinical and translational results of CALGB 40601. Proc ASCO 49th Annual Meeting. 2013. 31 May–3 June 2013;15 S (Abstract 500).

    Google Scholar 

  37. Carey LA, Berry DA, Ollila D, et al. (2013) Clinical and translational results of CALGB 40601. Proc ASCO 49th Annual Meeting. May 31-June 3, 2013; 15 S (Abstract 500).

    Google Scholar 

  38. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  39. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.

    Article  Google Scholar 

  40. Bear HD, Tang G, Rastogi P, Geyer CE Jr., Robidoux A, Atkins JN, et al. The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-4037 the San Antonio Breast Cancer Conference 9–13 Dec 2014, San Antonio; Meeting Abstract (PD2-1).

    Google Scholar 

  41. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab – results of the randomised GeparQuinto study (GBG 44). Eur J Cancer. 2013;49(10):2284–93.

    Article  CAS  PubMed  Google Scholar 

  42. Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 2000;83(11):1480–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7.

    Article  PubMed  Google Scholar 

  44. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.

    Article  Google Scholar 

  45. Frasci G, D’Aiuto G, Comella P, D’Aiuto M, Di Bonito M, Ruffolo P, et al. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol. 2010;21:707–16.

    Article  CAS  PubMed  Google Scholar 

  46. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17:3412–7.

    CAS  PubMed  Google Scholar 

  47. Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003;14:227–32.

    Article  CAS  PubMed  Google Scholar 

  48. Smith IE, A’Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, TOPIC Trial Group, et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neoadjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004;15:751–8.

    Article  CAS  PubMed  Google Scholar 

  49. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

    Article  PubMed  Google Scholar 

  50. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, I-SPY 1 TRIAL Investigators, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3):1049–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL – CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. von Minckwitz G, Blohmer JU, Untch M, Costa SD, Eidtmann H, Fasching PA et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients – results of the GeparTrio Trial. Proc SABCS 34th Annual San Antonio Breast Cancer Symposium 15 Dec 2011. Cancer Res 71. 2011:24(S 3):S3–2.

    Google Scholar 

  53. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22(12):2294–302.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Istanbul University Institute of Oncology, Topkapi, Istanbul, 34390, Turkey

    Yesim Eralp MD

Authors
  1. Yesim Eralp MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yesim Eralp MD .

Editor information

Editors and Affiliations

  1. Inst of Oncology,Ist Tıp Fak, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. General Surgery, Istanbul Univ Istanbul Fac of Med, Istanbul, Turkey

    Abdullah İgci

  3. Breast Surgery,, Magee-Womens Hospital, Pittsburg, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Eralp, Y. (2016). Preoperative Therapy for Operable Breast Cancer. In: Aydiner, A., İgci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-26012-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26012-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26010-5

  • Online ISBN: 978-3-319-26012-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation